LL-37 is the human cathelicidin-derived antimicrobial peptide, a 37-amino-acid fragment of the hCAP18 precursor. It is a naturally occurring part of the innate immune system, found in neutrophils, skin, and epithelial surfaces.

What does research suggest LL-37 does?

Preclinical and in-vitro studies report antimicrobial activity (disrupting microbial membranes) and immune-modulating roles. Most of this evidence comes from cell and animal models; direct human clinical evidence is limited and largely mechanistic.

Is LL-37 an approved medicine?

No. LL-37 is not an approved medicine. Material available on the research market has research-chemical status and is not authorized for human use or treatment of any condition.

Human safety data is limited, and unregulated research-market material is unverified. Because LL-37 is an immune peptide involved in complex inflammatory pathways, its safety profile is not established, and its long-term effects in humans are unknown.

What are the potential side effects of LL-37?

There is no well-characterized human side-effect profile. Its long-term profile is unknown, and research has also linked cathelicidin activity to inflammatory and autoimmune processes, so effects cannot be assumed to be benign.

What is the legal status of LL-37?

LL-37 is not approved as a medicine and is generally handled as a research chemical, with commercial availability restricted. Legal status varies by jurisdiction, and it is not sold or intended as a consumer health product.

Is LL-37 a natural human molecule or a lab invention?

It is naturally occurring. LL-37 is the active fragment of hCAP18, the only cathelicidin the human body makes, and it is found in cells such as neutrophils and in tissues like skin. Research-market versions are synthetic copies of this natural sequence, which is a different thing from the peptide your body produces in a regulated way.

Why does LL-37 come up in discussions of both fighting infection and skin conditions?

Because it plays a double-edged biological role. As a host-defense peptide it can disrupt microbes, but it also signals to immune cells, and dysregulated LL-37 activity has been studied in the context of inflammatory skin conditions. This is why the same molecule appears in seemingly opposite conversations. It reflects biological complexity, not a proven use.

How is LL-37 different from a conventional antibiotic?

Conventional antibiotics are typically small molecules targeting specific bacterial machinery, and they are approved drugs with defined dosing. LL-37 is a larger peptide that acts on microbial membranes and also influences immune signaling. Importantly, it has not gone through the approval process that antibiotics have, so the comparison is mechanistic and academic rather than practical.

Where can I buy LL-37 and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Antimicrobial / Immune

Buy LL-37 – Vendors, Prices, Testing and Evidence

Buy LL-37

Also known as: Cathelicidin fragment

Evidence grade C — Early / Preclinical

Short answer

An antimicrobial peptide studied for immune and antimicrobial roles. Mostly preclinical.

Where can you buy LL-37?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

LL-37 is a human cathelicidin-derived antimicrobial peptide.

What is not established?

Limited; largely mechanistic and preclinical.

Safety

Human safety data is limited; research-market material is unverified.

Regulatory status

Not an approved medicine. Research chemical status.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Vendor comparison

Buy LL-37: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	LL-37 research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

LL-37 research product

Code PEPTIDES10 −10% · discount code details

What is it?

LL-37 is a human cathelicidin-derived antimicrobial peptide.

Research and evidence

LL-37 is the only known human cathelicidin-derived antimicrobial peptide, a 37-amino-acid fragment released from the precursor protein hCAP18. As a naturally occurring component of the innate immune system, it is found in neutrophils, epithelial surfaces, sweat, and skin, where it forms part of the body's first line of host defense. On peptides.cx it is catalogued in the Antimicrobial / Immune category, and it is important to be clear at the outset: LL-37 is not an approved medicine. Material sold on the research-chemical market carries research-chemical status, is unverified, and is not intended for human use.

LL-37 is studied because it sits at the intersection of two functions that interest researchers: direct antimicrobial activity and broader immune modulation. In laboratory and preclinical work it has been reported to disrupt bacterial membranes and to influence immune signaling, wound-related processes, and inflammatory pathways, which is why much of the discussion around it centers on immune support and skin biology. However, the honest evidence picture is modest. The bulk of what is known comes from in-vitro (cell and test-tube) experiments and animal models; direct human clinical evidence remains limited and largely mechanistic. peptides.cx assigns LL-37 an evidence grade of C, reflecting that its roles are biologically well-characterized in principle but not established through controlled human outcome trials.

Because LL-37 is an endogenous immune peptide, its biology is genuinely complex — the same molecule that shows antimicrobial and immune-modulating activity has also been linked in research contexts to inflammatory and autoimmune processes, underscoring that "natural" does not mean simple or automatically beneficial. Long-term human safety data is limited, and the profile of unregulated research-market material is unknown. This page summarizes what LL-37 is, why it is researched, and where the evidence currently stands, so readers can understand the science accurately rather than the marketing. It is educational reference information only and is not medical advice.

Evidence grade: C

Limited; largely mechanistic and preclinical. Antimicrobial and immune effects reported.

Human evidence

Limited; largely mechanistic and preclinical.

Animal and preclinical evidence

Antimicrobial and immune effects reported.

Proposed mechanisms

Antimicrobial activity
Immune-modulating roles

Safety concerns and known side effects

Human safety data is limited; research-market material is unverified.

Unknown long-term profile

Regulatory status

Not an approved medicine. Research chemical status.

LL-37 research timeline

1980s
Cathelicidins are identified as a family of host-defense (antimicrobial) peptides in mammals, setting the stage for finding a human member.
mid-1990s
The sole human cathelicidin (hCAP18) is characterized and its released C-terminal peptide is named LL-37, after its two leading leucine residues and length of 37 amino acids.
late 1990s
Early preclinical work describes LL-37's broad antimicrobial activity against bacteria and its presence in neutrophils, skin, and other tissues.
2000s
Research broadens beyond killing microbes to immune-modulating roles, and LL-37 is implicated in skin conditions and wound-healing biology in laboratory and animal studies.
2010s
Preclinical interest expands to areas such as antimicrobial resistance and possible anticancer signaling, while human clinical evidence remains sparse.
early 2020s
LL-37 continues to be studied largely at the mechanistic and preclinical level; it is not an approved medicine and circulates in research-chemical channels with unverified material quality.

Frequently asked questions about LL-37

What is LL-37?: LL-37 is the human cathelicidin-derived antimicrobial peptide, a 37-amino-acid fragment of the hCAP18 precursor. It is a naturally occurring part of the innate immune system, found in neutrophils, skin, and epithelial surfaces.
What does research suggest LL-37 does?: Preclinical and in-vitro studies report antimicrobial activity (disrupting microbial membranes) and immune-modulating roles. Most of this evidence comes from cell and animal models; direct human clinical evidence is limited and largely mechanistic.
Is LL-37 an approved medicine?: No. LL-37 is not an approved medicine. Material available on the research market has research-chemical status and is not authorized for human use or treatment of any condition.
Is LL-37 safe?: Human safety data is limited, and unregulated research-market material is unverified. Because LL-37 is an immune peptide involved in complex inflammatory pathways, its safety profile is not established, and its long-term effects in humans are unknown.
What are the potential side effects of LL-37?: There is no well-characterized human side-effect profile. Its long-term profile is unknown, and research has also linked cathelicidin activity to inflammatory and autoimmune processes, so effects cannot be assumed to be benign.
What is the legal status of LL-37?: LL-37 is not approved as a medicine and is generally handled as a research chemical, with commercial availability restricted. Legal status varies by jurisdiction, and it is not sold or intended as a consumer health product.
Is LL-37 a natural human molecule or a lab invention?: It is naturally occurring. LL-37 is the active fragment of hCAP18, the only cathelicidin the human body makes, and it is found in cells such as neutrophils and in tissues like skin. Research-market versions are synthetic copies of this natural sequence, which is a different thing from the peptide your body produces in a regulated way.
Why does LL-37 come up in discussions of both fighting infection and skin conditions?: Because it plays a double-edged biological role. As a host-defense peptide it can disrupt microbes, but it also signals to immune cells, and dysregulated LL-37 activity has been studied in the context of inflammatory skin conditions. This is why the same molecule appears in seemingly opposite conversations. It reflects biological complexity, not a proven use.
How is LL-37 different from a conventional antibiotic?: Conventional antibiotics are typically small molecules targeting specific bacterial machinery, and they are approved drugs with defined dosing. LL-37 is a larger peptide that acts on microbial membranes and also influences immune signaling. Importantly, it has not gone through the approval process that antibiotics have, so the comparison is mechanistic and academic rather than practical.
Where can I buy LL-37 and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

ImmuneSkin

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10